Tax Reform Provides Environment For M&A Surge, EY Report Says

2018 should see an increase in significant biopharma deal-making, possibly even a mega-merger, as US companies are able to repatriate offshore cash at lower tax rates.

US dollars

US tax reform legislation signed into law this past December is expected to help spur an increase in biopharma M&A activity in 2018, including the possibility for mega-mergers, possibly even a deal in which one of the big pharma companies absorbs another – a result not seen since the industry-changing events of 2009.

This is among the projections provided in EY's 2018 M&A Firepower Report, issued Jan. 8 to preview the year ahead...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.